natgillin/translations-raw huggingface dataset:
With a view to consumer acceptance manufacturers of beverages and foodstuffs generally do not like to use such chemical or artificial additives but, instead; prefer to employ additives that make more appealing ingredient labels (consumer-friendly labels) possible and that deliver similar functionality. 
S obzirom na prihvaćanje od strane potrošača, proizvođači pića i prehrambenih proizvoda općenito ne vole upotrebljavati kemijske ili umjetne aditive, nego, umjesto toga, radije upotrebljavaju aditive koji omogućuju veću privlačnost deklaracija (deklaracije prihvatljive potrošačima), i koji pružaju sličnu funkcionalnost.
in an inert solvent or else without solvent with a compound of the formula (III) to a compound of the formula (VII) in which R1A, R3 and T3 are each as defined above, reacting the compound of formula (VII) in an inert solvent with chlorosulphonyl isocyanate to give a compound of the formula (IV) and 
RR. | (VII) gdje R'", R? i T? su svaki kako je gore definirano, ovo nakon toga reagira u inertnom otapalu s klorosulfonil izocijanatom da se dobije spoj s formulom (IV) i ovo se potom prevodi analogno postupku [A] u spoj s formulom (I-1),
The method of claim 8, wherein the concentration of LIF in the medium is about 100 U/mL, the MEK pathway inhibitor is MEK inhibitor PD0325901 at a concentration of about 1 µM, and the GSK3 inhibitor is CHIR99021 at a concentration of about 3 µM. 
Postupak sukladno patentnom zahtjevu 8, naznačen time, da je koncentracija LIF-a u medija oko 100 U/ml, inhibitor MEK puta je MEK inhibitor PD0325901 u koncentraciji od oko 1 uM 1 GSK3 inhibitor je CHIR99021 u koncentraciji od oko 3,0 uM.
According to a further major feature of the present invention, such tearing and deforming effect causes a kind of spout—as shown with a dashed line and generally indicated at 220 in FIG. 7 —in the lower membrane 210, wherein such spout comes to practically lie aligned along the common axis of the capsule 200, the two cup-shaped body portions 130 and 140, the bore 156 of the container 151, and the circular bore 123 in the horizontal arm 121 of the base member 110 . 
Prema daljnoj glavnoj karakteristici ovog izuma, takvo deranje i deformiranje dovodi do nastanka svojevrsnog mlaza kao što je prikazano isprekidanom crtom, a općenito je označeno s 220 na Slici 7 u donjoj membrani 210, gdje se takav mlaz praktički poravna sa zajedničkom osi kapsule 200, dva trupa u obliku šalice 130 1 140, provrtom 156 u spremniku 151 i kružnim provrtom 123 na horizontalnom kraku 121 osnovnog elementa 110.
The antibodies for the use of any one of claims 1-7, wherein the cancer is a solid tumor, or in particular an advanced refractory solid tumor, and is optionally chosen from cancer of the head or neck, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), melanoma, colorectal cancer, and serous ovarian carcinoma. 
Antitijela za primjenu iz bilo kojeg od patentnih zahtjeva 1-7, gdje rak je solidni tumor, ili naročito uznapredovali refraktorni solidni tumor, 1 po izboru je odabran od raka glave 1li vrata, nesitnostaničnog raka pluća (NSCLC), raka bubrežnih stanica (RCC), melanoma, kolorektalnog raka, i seroznog raka jajnika.
The feed according to claim 1, characterized in that it is a complete feed which contains the fatty acid mixture in an amount of 1-6% by weight, preferably 2-5% by weight and/or it is a concentrate feed which contains the fatty acid mixture in an amount of 2-10% by weight, preferably 3-8% by weight. 
Životinjska hrana prema zahtjevu 1, naznačeno time da je to potpuna životinjska hrana koja sadrži mješavinu masnih kiselina u iznosu od 1 do 6% težine, poželjno od 2 do 5% težine i/ili je koncentrat životinjske hrane koja sadrži mješavinu masnih kiselina u iznosu od 2 do 10% težine, poželjno od 3 do 8% težine.
Cylinder-piston system according to any one of the claims 1 to 9, characterized in that the first polymer material (C) and/or the second polymer material (P), particularly the second polymer material (C), comprises internal lubricants. 
Sustav cilindar-klip prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time što prvi polimerni materijal (C) i/ ili drugi polimerni materijal (P), naročito drugi polimerni materijal (C) sadrži unutarnja maziva.
The pharmaceutical composition as defined in claim 3 for use according to claim 12, wherein the Clostridium Difficile Associated Disease arises from or is exacerbated by a Nap1 Clostridium difficile infection. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što bolest je povezana s bakterijom Clostridium difficile posljedica ili je pogoršana infekcijom bakterijom Nap1 Clostridium difficile.
The method of claim 10, wherein said solid support is a disk made of non-woven polyester bonded to a sheet of polypropylene mesh. 
Postupak sukladan zahtjevu 10, naznačen time, da spomenuta kruta potpora je disk koji je načinjen od ne-utkanog poliestera koji je vezan za plohu polipropilenske mreže.
combining the compound according to claim 1 with a pharmaceutical excipient to form a pharmaceutical composition; 
(a) kombiniranje spoja u skladu s patentnim zahtjevom 1 s farmaceutskim ekscipijentom kako bi se dobilo farmaceutski pripravak;
incubating said starting liquid, the partly AX-REED treated liquid or the AX-REED liquid in said chamber whereby the direction of electric field is reversed at intervals, thereby obtaining a partly CX-REED treated liquid; 
IV. inkubiranje navedene početne tekućine u navedenoj komori pri čemu se smjer električnog polja preokreće u intervalima, te se tako dobiva djelomično obrađena tekućina AX-REED;
Formulation according to claim 2, characterized by that the excipient is antioxidant selected from the group consisting of 2,6-di- terc -butyl-4-hydroxytoluene (BHT), terc- butylhydroxyanisole (BHA), tocopherol, tocopheryl acetate, ascorbic acid, or mixtures of these substances. 
Formulacija prema zahtjevu 2, naznačena time da je pomoćna tvar antioksidans izabran iz grupe koja se sastoji od 2,6-di-terc-butil-4-hidroksitoluena (BHT), ferc-butilhidroksianisola (BHA), tokoferola, tokoferil acetata, askorbinske kiseline, ili smjese navedenih tvari.
The compound which is or a pharmaceutically acceptable salt thereof. 
Spoj 37 ili njegova farmaceutski prihvatljiva sol, ester, solvata ili njihov hidrat.
The pharmaceutical composition for use of claim 2, wherein said quinolone carboxylic acid derivative is a crystalline D-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylate characterized by an X-ray powder diffraction pattern substantially in accordance with that shown in FIG. 
Farmaceutska kompozicija za uporabu prema patentnom zahtjevu 2, pri čemu je navedeni derivat kinolon karboksilne kiseline kristalni D-glucitol, 1-deoks1-1-(metilamino)-, 1-(6-amino-3,5-difluoro-2-piridinil)-8-kloro-6fluoro-1,4-dihidro-7-(3-hidroksi-1-azetidinil)-4-okso-3-kinolinkarboksilat naznačen rendgenskim difraktogramom praha koji je suštinski u skladu s onim prikazanim da SL.
The biocompatible implant according to claim 1 wherein the linker is a polyether. 
Biokompatibilni usadak u skladu s patentnim zahtjevom 5, naznačen time što je spojnica polieter.
The method according to claim 1, wherein the endothermic condensation reaction is represented by the following formula: 
Postupak prema bilo kom od zahtjeva 1 do 6, pri čemu je endotermna reakcija kondenzacije predstavljena sljedećom formulom:
An antibody polypeptide according to claim 1 wherein the antibody polypeptide is linked, directly or indirectly, to a therapeutic moiety. 
Polipeptid antitijela prema bilo kojim prethodnim zahtjevima, pri čemu je polipeptid antitijela povezan, direktno ili indirektno, sa terapijskim dijelom.
After chromatography on silica gel (50:50:5 benzene-cyclohexane-ethanol) the product had m.p. 
Nakon kromatografije na silika gelu (50:50:5 benzen-cikloheksan-etanol) produkt ima t. t.
The aqueous formulation of any one of the claims 1 to 10, wherein the pH is 4. 
Vodena formulacija u skladu s patentnim zahtjevom 9, naznačena time što je pH 4.
A compound of Formula I: or a pharmaceutically acceptable salt, ester or prodrug thereof for use in a method of treating a opioid toxicity or overdose in a subject in need thereof comprising administrating a first opioid receptor antagonist followed by the compound, wherein; 
Spoj koji sadrži formulu: za uporabu u postupku liječenja opioidne toksičnosti ili predoziranja kod subjekta kojem je potrebno sadrži isporuku prvog antagonista receptora opioida nakon čega slijedi taj spoj.
A polypeptide comprising an IgG Fc variant of a parent polypeptide, wherein said parent polypeptide comprises an IgG constant domain and wherein said Fc variant comprises a serine at position 434 and an isoleucine or a valine at position 311, and wherein numbering is according to the EU index in Kabat et al. 
Antitijelo koje sadrži dvije modifikacije u odnosu na divlji tip humane Fc regije, naznačeno time da su navedene modifikacije 428L i 434S, pri čemu navedeno antitijelo ima kod sisavca duži poluživot u odnosu na antitijelo bez navedenih modifikacija, i pri čemu je numeriranje u skladu s EU indeksom u Kabat i sur., za uporabu kao lijek.
(b10) an antigen-binding site comprising an H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 135, 136, and 137 (H chain CDRs of J346), respectively; and (b11) an antigen-binding site comprising an H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 174, 175, and 176 (H chain CDRs of J142), respectively. 
(b10) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1, 2 i 3 od SEQ ID NO: 135, 136 odnosno 137 (H-lanac CDR-područja od J346); i (b11) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1, 2 i 3 od SEQ ID NO: 174, 175 odnosno 176 (H-lanac CDR-područja od J142); ili
The antibody-like binding protein of any one of claim 1, 2, 5, 6, 9, or 10, wherein the binding protein is bispecific and capable of binding two different antigen targets. The antibody-like binding protein of claim 16, wherein the two different antigen targets are selected from the group consisting of IL4 and IL13, IGF1R and HER2, IGF1R and EGFR, EGFR and HER2, BK and IL13, PDL-1 and CTLA-4, CTLA4 and MHC class II, IL-12 and IL-18, IL-1a and IL-1B, TNFa and IL12/23, TNFa and IL-12p40, TNFa and IL1B, TNFa and IL-23, and IL17 and IL23. 
Protutijelu sličan vezivni protein prema bilo kojem od zahtjeva 1, 2, 5 ili 6, naznačen time da vezivni peptid je bispecifičan i može vezati dva različita antigenska cilja, pri čemu, poželjno, dva različita antigenska cilja se biraju iz skupine koju čine ILA i 1L13, IGFIR i HER2, IGFIR i EGFR, EGFR i HER2, BK i IL13, PDL-1 i CTLA-4, CTLA4 1 MHC razred II, IL-12 i 1L-18, IL-1aiIL-18, TNFa.i IL12/23, TNFa i IL-12p40, TNFa.i IL18, TNFa i IL- 23,11L1711L23.
The composition of claim 1, further comprising at least one compound selected from sulfisoxazole, methimazole, prilocaine, dyphylline, quinacrine, carbenoxolone, aminocaproic acid, cabergoline, diethylcarbamazine, cinacalcet, cinnarizine, eplererone, fenoldopam, leflunomide, levosimendan, sulodexide, terbinafine, zonisamide, etomidate, phenformin, trimetazidine, mexiletine, ifenprodil, moxifloxacin, bromocriptine or torasemide, or a pharmaceutically acceptable salt thereof 
Smjesa za uporabu prema zahtjevu 1, dalje sadrži barem jedan dodatni spoj izabran iz grupe koja obuhvaća sulfizoksazol, metimazol, prilokain, difiln, kvinakrin, karbenoksolon, aminokaproičnu kiselinu, kabergolin, dietilkarbamazin, sinakalcet, cinarizin, eplerenon, fenoldopam, leflunomid, levosimendan, sulodeksid, terbinafin, zonisamid, etomidat, fenformin, trimetazidin, meksiletin, ifenprodil, moksifloksacin, bromokriptin ili torasemid, ili njihove farmaceutski prihvatljive soli.
The method according to claims 9 or 10, wherein the reach of spray of the individual spray heads (17A-E) is being inspected, by registering the cone and/or cloud of smoke exiting from the spray head. 
Postupak sukladno zahtjevima 9 ili 10, pri čemu je doseg spreja individualnih štrealjki (17A-E) ispitivan, registriranjem stošca i/ili oblaka dima koji izlazi iz štrcaljke. 12.
R1a is alkyl which may be substituted by A, cycloalkyl which may be substituted by A, alkenyl which may be substituted by A, alkynyl which may be substituted by A, aryl or a heterocyclic group; X is alkyl, alkenyl, alkynyl, halogen, haloalkyl, cyano, or nitro,; is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, or aryl; is alkyl: 
(i-1) naznačen time, da je R'* alkil koji može biti supstituiran sa A, cikloalkil koji može biti supstituiran sa A, alkenil koji može biti supstituiran sa A, alkinil koji može biti supstituiran sa A, arilom ili heterocikličkom skupinom; X je alkil, alkenil, alkinil, halogen, haloalkil, cijano, ili nitro; R je vodik, alkil, alkenil, alkinil, haloalkil ili aril;
adding a compound of formula II wherein R1, R2 and R3 have the meanings as described under formula I, in the presence of an inert organic solvent to a mixture comprising an organic nitrite of formula III R4-O-N=O (III), wherein R4 is C1-C8alkyl, a compound of formula IV and an inert organic solvent; 
te navedeni postupak obuhvaća dodavanje spoja s formulom II [image] pri čemu R1, R2 i R3 imaju značenja kao što je opisano pod formulom I, u prisutnosti inertnog organskog otapala u smjesu koja sadrži organski nitrit s formulom III
A pharmaceutical composition in the form of an oral dosage form, comprising from 70 mg to 750 mg of the hemisulfate salt of Compound (I) according to claim 1. 
Farmaceutska kompozicija u formi oralnog doznog oblika, koji sadrži od 70 mg do 750 mg hemisulfat soli spoja (1) u skladu sa patentnim zahtjevom 1.
An anti-FcRn antibody according to any one of aspects 1 to 11, wherein the antibody is a full length antibody. An anti-FcRn antibody according to aspect 16 wherein the full length antibody is selected from the group consisting of an IgG1, IgG4 and IgG4P. 
Anti-FcRn antitijelo prema patentnom zahtjevu 1, naznačen time, što je antitijelo antitijelo pune dužine, opcionalno naznačeno time, što je antitijelo pune dužine odabrano iz skupine koja se sastoji od IgG1, IgG4 i IeG4P.
the package (10) has an overall height between 2.3m and 2.5m and more particularly of about 2.4m. Package (10) comprising a multitude of packages of panels (22a, 22b, 22c, 22d, 22e, 22f, 22g, 22h) of mineral wool, especially fibre glass insulating material, wherein 
L Paket (10) koje sadrži veći broj valjaka (Ta, Ib, Ic, Id, 2a, 2b, 2c, 2d) ili paketa ploča (224, 22b, 22c, 22d, 22e, 22f, 22g,22h) mineralne vune, osobito izolacijskog materijala od staklene vune, pri čemu
a T cell receptor B-chain comprising the T cell receptor B-chain sequence of SEQ ID NO: 45. A nucleic acid encoding the T cell receptor chain or T cell receptor according to claim 1 or 2 or a cell comprising the T cell receptor chain or T cell receptor according to claim 1 or 2 or said nucleic acid. 
Postupak sukladno patentnom zahtjevu 1 ili 2, naznačen time što navedeni korak osiguravanja nukleinske kiseline koja kodira T stanični receptor koji ima specifičnost T staničnog receptora navedene T stanice reaktivne na jedan antigen sadrži osiguravanje nukleinske kiseline koja kodira T stanični receptor koji sadrži najmanje CDR sekvence, poželjno najmanje varijabilno područje T staničnog receptora navedene T stanice reaktivne na jedan antigen.
wherein the wavy line indicates the attachment site for the linker. 
MIMA gdje valovita linija pokazuje na mjesto priključenja skupine za povezivanje.
Preferably, the bacterial strain for use in the invention has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:1 or SEQ ID NO:3. 
Sastav za upotrebu prema zahtjevu 7, gdje bakterijski soj ima 16s rRNK sekvencu koja je najmanje 97%, 98%, 99%, 99.5% ili 99.9% identična sa SEQ ID NO:5 ili koja ima 16s rRNK sekvencu SEQ ID NO:5.
Method for treating water at low cost, according to claim 2, wherein the Langelier Saturation Index or Stiff & Davis Saturation index is kept under 2 by a process selected from pH adjustment, the addition of antiscalants, or a water softening process. 
Postupak za obradu vode uz nizak trošak, prema zahtjevu 1, naznačen time što se Langelierov indeks zasićenja i Stiff & Davisov indeks zasićenja drži ispod 2 postupkom odabranim od podešavanja pH, dodavanja antiskalanta, ili postupkom omekšavanja vode.
The following are preferred examples of the disclosure: 
Datum objave europskog patenta:
The 5a-androstane-3B,5,6B-triol for use according to claim 1, wherein the neuron damage is caused by hypoxia. 
5o-androstan-3B,5,6f-triol za uporabu u skladu s patentnim zahtjevom 1, pri čemu je oštećenje neurona uzrokovano hipoksijom.
The method according to claim 16, wherein the amount of HCl used per amount of compound of formula (III) in step b) is from about 0.07 to about 0.10 molar equivalents. 
Proces prema bilo kojem patentnom zahtjevu od 2 do 11, naznačen time, što se količina korištenog HCl-a na količinu spoja formule (III) u koraku e) kreće od oko 0,05 do oko 0,2, poželjno od oko 0,07 do oko 0,10 molarnih ekvivalenata.
A nucleic acid encoding a protein of claim 1. A vector comprising the nucleic acid molecule of claim 2. 
Vektor koji sadrži molekulu nukleinske kiseline prema patentnom zahtjevu 6, opcionalno naznačen time da;
The compound of formula (I), or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein n is 1, 2 or 3; 
Spoj formule (I), [image] ili njegova farmaceutski prihvatljiva sol, naznačen time, da n je 1, 2 ili 3;
• comparing said pushing force (Fp) with an activation level (Fon) for activating electric propulsion, and 
* uspoređivanja navedene potisne sile (F,) s razinom aktivacije (F,,) za aktiviranje električnog pogona, i
A pharmaceutical composition comprising a pharmaceutical excipient and an antivirally-effective amount of the compound of any one of claims 1 or 2. 
Farmaceutska smjesa, naznačena time, što sadrži farmaceutski ekscipijent i protiv virusa efikasnu količinu spoja iz bilo kojeg od zahtjeva 1 do 3.
The integrated circuit of claim 1, wherein the MRAM module is formed as a three-dimensional (3D) heterogeneous architecture comprising the MRAM main memory formed on one or more main memory planes, and the MRAM last level cache and a logic layer are integrated on a heterogeneous plane parallel to the or more main memory planes. 
Integralni krug prema Zahtjevu 1, naznačen time što je MRAM modul formiran u trodimenzionalnoj (3D) heterogenoj arhitekturi koja sadrži MRAM glavnu memoriju formiranu u jednoj ili više ravnina glavne memorije, i gdje su MRAM cache memorija posljednje razine i logički sloj integrirani u heterogenoj ravnini paralelnoj u odnosu na jednu ili više ravnina glavne memorije.
A continuous culturing device comprising (a) a scaffold formed by a matrix of interconnected growth surfaces spaced at regular intervals and (b) a fluid distribution means at the inlet and the exit of the growth areas, wherein the interconnected growth surfaces are spaced at regular intervals equal or larger than 0.7 mm and smaller than 3.0 mm 
Skele pogodne za rast tkiva in vivo formirane matricom međusobno povezanih površina rasta koje su definirane međusobnim povezivanjem brojnih vlakana ili trodimenzionalnih struktura i postavljene na pravilnim razmacima jednakim ili većim od 0.7 mm i manjim od 3.0 mm, pri čemu su međusobne veze brojnih vlakana ili trodimenzionalnih struktura jednako raspoređene tako da formiraju otvorene prostore.
Embodiment 206 A pharmaceutical composition comprising a peptide according to any of embodiments 1 to 176 or an immunoconjugate according to any of embodiments 202 to 205 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži antitijelo prema bilo kojem zahtjevu od 1 do 8, imunokonjugat prema zahtjevu 13 ili bispecifičnu ili multispecifičnu molekulu prema zahtjevu 14 ili 15 te farmaceutski prihvatljiv nosač.
A pharmaceutical composition comprising an antibody of any one of claims 1-13 and/or a conjugate of claim 15, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav obuhvaća protutijelo iz bilo kojeg od patentnih zahtjeva 1 do 5 i/ili konjugat iz patentnog zahtjeva 7 i farmaceutski prihvatljivi nosač.
used in the form of a salt; and/or 
koristi u obliku soli; i/ili
In the most preferred embodiment the M3 antagonist of the invention and the PDE4 inhibitor are both present in the same pharmaceutical composition and are administered by inhalation through a common delivery device. 
U najpoželjnijem utjelovljenju, M3 antagonist sukladno predmetnom izumu I (32-agonist se nalaze u istom farmaceutskom pripravku i primjenjuju se inhalacijom putem zajedničke naprave za isporuku.
102 e) are cut from an upper edge of the ridge portion (128) down to various levels between said upper edge and the lowermost part of said longitudinally extending pocket (135). The key as defined in claim 41, wherein said side code recesses (102 a . . . 
Ključ kako je definiran u zahtjevu 11, naznačen time da su navedena bočna kodna udubljenja izrezana od gornjeg ruba dijela grebena prema dolje do različitih razina između navedenog gornjeg ruba i najnižeg dijela navedenog džepa koji se pruža uzdužno.
The force required to move the nozzle 12 depends on the tightness of the connection between the plate 300 and the air pipe 304, and is preferably in the range from 2 to 4 N. The nozzle 12 is preferably moveable within a range of ±10° from an untilted position, in which the axis X is substantially horizontal, to a fully tilted position. 
Ventilatorski sustav prema zahtjevu 14, gdje je os (X) nagnuta za kut u rasponu od 5 do 15" kada se izlaz zraka (14) pomakne iz nenagnutog položaja u potpuno nagnuti položaj.
A single dose of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof for use in the treatment of acute exacerbations of chronic obstructive pulmonary disease. 
Pojedinačna doza 3-[5-amino-4-(3-cijanobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamida ili njegove farmaceutski prikladne soli, hidrata ili solvata za uporabu u liječenju akutnih pogoršanja (egzacerbacija) kronične opstruktivne plućne bolesti.
said at least two code recesses in each group having generally different depths, 
- < navedena barem dva kodna udubljenja u svakoj skupini imaju općenito različite dubine,
complex PET (Positron Emissions Tomography), SPECT (Single Photon Emissions Computed Tomography) Fluorescent pigments/chromophores such as the following were used: Fluorescein, Rhodamin, Coumarin, BODIPY, Pyrene (Cascade Blue), Lucifer Yellow, Phycobiliprotein, Cyanin, AlexaFluoro, Oregon Green, Texas Red and their derivatives. 
Derivati peptida GLP-1 u skladu s prethodnim patentnim zahtjevima, naznačeni time što fluorescentna bojila se osobito bira iz skupine koju čine fluorescein, rodamin, kumarin, BODIPY, piren (kaskadno modrilo), lucifersko žutilo, fikoobiliprotein, cijanin, aleksa fluor, oregonsko zelenilo, teksaško crvenilo, kumarin i njihovi derivati.
Process according to claim 19, characterised in that 20 %, preferably 50 %, more preferably 80 %, and most preferably 100 % by weight of the polymer is added to said slaked lime suspension prior to step (iii). 
Postupak prema zahtjevu 19, naznačen time da se dodaje 20 %, poželjno 50 %, poželjnije 80 %, te najpoželjnije 100 % težinski polimera u navedenu suspenziju gašenog vapna prije koraka (iii).
a C-terminal peptide having at least 90% amino acid identity with the amino acid sequence starting at an amino acid residue selected from the group consisting of any one of the amino acid residues located at positions 401 to 406 of SEQ ID N°1 and ending at the amino acid residue located at position 494 of SEQ ID N°1, wherein: 
N-terminalni peptid koji je najmanje 90% aminokiselinski istovjetan aminokiselinom slijedu koji počinje aminokiselinskim ostatkom smještenim na položaju 1 u SEQ ID No: 1, a završava aminokiselinskim ostatkom kojeg se bira iz skupine koju čine bilo koji od aminokiselinskih ostataka smještenih na položajima 99 do 173 u SEQ ID No: 1; i